248 results on '"Yendamuri S"'
Search Results
2. P1.09-07 Obesity Promotes Lung Carcinogenesis Through T-cell Immune Dysfunction
3. Examination of Cancer Cell-lines to Elucidate Effect of Radiation on Tumor Antigen Presentation in Anti-Tumoral Immune Response: Topic: Radiation Oncology: OA01.06
4. ASO Author Reflections: To Med or Not to Med? That is the Question
5. Systematic Review of Single-Fraction Stereotactic Body Radiation Therapy for Early Stage Non-Small-Cell Lung Cancer and Lung Oligometastases: How to Stop Worrying and Love One and Done
6. P48.09 Body Mass Index Predicts Benefit From Adding Metformin to EGFR-TKIs in Patients With Lung Adenocarcinoma: Subanalysis From an RCT
7. OA12.02 Metformin has Divergent Effects on the Tumor Immune Microenvironment of Non-Small Cell Lung Cancer (NSCLC) Depending on Obesity
8. The role of microRNA in human leukemia: a review
9. MA08.05 A Multi-Center Analysis of Right vs Left-Sided Pneumonectomy Following Induction Therapy
10. Prevalence and Significance of APOBEC-Mediated RNA Editing in Lung Cancer Tumors
11. MA23.09 Minimally Invasive Approaches Do Not Compromise Outcomes for Pneumonectomy, a Comparison Utilizing the National Cancer Database
12. OA01.06 Examination of Cancer Cell-lines to Elucidate Effect of Radiation on Tumor Antigen Presentation in Anti-Tumoral Immune Response
13. Minimally Invasive Approaches Do Not Compromise Outcomes for Pneumonectomy: A Comparison Using the National Cancer Database.
14. Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in breast cancer cell lines
15. Regression of upper gastric cancer in mice by FHIT gene therapy
16. The Prognostic Utility of Log Odds Ratios in Non-Small Cell Lung Cancer (NSCLC)
17. Accuracy of Histological Classification of Needle Biopsy/Aspirate Specimens in Patients With Non-Small Cell Lung Cancer (NSCLC)
18. Perioperative Outcomes of Patients With Less Than Clinical N2 NSCLC Receiving Neoadjuvant Vs. Adjuvant Therapy
19. Outcomes in Patients 65 Years or Older Treated with Trimodality Therapy for Esophageal Carcinoma
20. Response-based outcomes in patients with esophageal cancer treated with primarily non-cisplatin and 5-fluorouracil–based trimodality therapy.
21. The effect of smoking history on response and survival outcomes patients with in esophageal cancer treated with neoadjuvant concurrent chemoradiotherapy followed by surgery.
22. Lung Cancer After Head and Neck Cancer: A 27-Year Single Institution Experience
23. Gene expression profile (GEP) for the prediction of pathologic complete response (pCR): Preliminary data from a neoadjuvant study of capecitabine (C), oxaliplatin (OXP), and radiation (RT) for esophageal cancer (EC).
24. Synchronous Non Small Cell Lung Cancers Should Not Be Classified as Stage IV - A Seer Database Analysis
25. Outcomes of Thoracoscopic Anatomic Resections in Patients with Limited Pulmonary Reserve
26. A single institution experience with neoadjuvant chemoradiation (CRT) with irinotecan (I) and cisplatin (C) in locally advanced esophageal carcinoma (LAEC)
27. Renal atrophy secondary to chemoradiation treatment of abdominal malignancies
28. Aortic paraganglioma requiring resection and replacement of the aortic root
29. 3p and 10q deletions detected by fluorescence in situ hybridization (FISH): A potential new tool for early detection of non-small cell lung cancer (NSCLC)
30. Esophageal tumor length is independently associated with long-term survival.
31. Mediastinoscopy and Mediastinal Lymph Node Dissection for Lung Cancer
32. Effect of the number of lymph nodes examined on the survival of patients with stage I nonsmall cell lung cancer who undergo sublobar resection.
33. Factors affecting the yield of microRNAs from laser microdissectates of formalin-fixed tissue sections
34. Analytical variables influencing the performance of a miRNA based laboratory assay for prediction of relapse in stage I non-small cell lung cancer (NSCLC)
35. Familial cancer associated with a polymorphism in ARLTS1
36. Familial cancer associated with a polymorphism in ARLTS1.
37. Restoration of receptor-type protein tyrosine phosphatase function inhibits human pancreatic carcinoma cell growth in vitro and in vivo
38. Tumor suppressor functions of ARLTS1 in lung cancers
39. Therapy of human pancreatic carcinoma based on suppression of HMGA1 protein synthesis in preclinical models
40. Initial Patient Characteristics of TSOG 102: A Multicenter Prospective Registry of Active Surveillance in Patients with Multiple Ground Glass Opacities.
41. Biomarker-Driven Personalized Immunoprevention: Toward More Efficient Clinical Trials?
42. Sex-based differences in the lung immune microenvironment are associated with an increased risk of lung cancer in women.
43. Epidemiology and Survival of Malignant Central Airway Obstruction in Lung Cancer Identified on Cross-Sectional Imaging.
44. Association of socio-demographic factors with clinical outcome among hospitalized patients in first and second waves of COVID-19 pandemic: Study from the developing world.
45. Rothia in Nonsmall Cell Lung Cancer is Associated With Worse Survival.
46. Correlation of Bronchoscopy and CT in Characterizing Malignant Central Airway Obstruction.
47. Survivin in lung cancer: a potential target for therapy and prevention-a narrative review.
48. Lung cancer in females-sex-based differences from males in epidemiology, biology, and outcomes: a narrative review.
49. Neoadjuvant therapy in non-small cell lung cancer: basis, promise, and challenges.
50. Diabetes and Immune Checkpoint Inhibitors-Letter.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.